In another study, higher expression of YAP1 was associated with worse progression-free survival in patients with epidermal growth factor receptor (EGFR)-mutant NSCLC treated with first-line EGFR tyrosine kinase inhibitors (13). The gene discussed is YAP1; the disease is non-small cell lung carcinoma.